株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

がん増殖阻害剤の市場および臨床パイプラインの分析

Cancer Growth Inhibitors Market & Clinical Pipeline Analysis

発行 KuicK Research 商品コード 328387
出版日 ページ情報 英文 1000 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
がん増殖阻害剤の市場および臨床パイプラインの分析 Cancer Growth Inhibitors Market & Clinical Pipeline Analysis
出版日: 2015年04月01日 ページ情報: 英文 1000 Pages
概要

世界の製薬業界ではこれまでにも数々のがん治療薬が、長年の研究と多額の投資の末に開発されてきました。現在も、毎年多くのがん治療薬が新たに上市されています。大手製薬企業は研究開発 (R&D) 活動に多額の資金を投資して臨床パイプラインの拡充を進めており、がん阻害剤の市場競争は今後さらに活発化するでしょう。

当レポートでは、全世界のがん増殖阻害剤の治験進行状況について分析し、技術上の特性や主な市場促進・抑制要因、主な薬剤 (がんチロシンキナーゼ、HDAC阻害剤、MTORタンパク質阻害剤、PI3K阻害剤、プロテアソーム阻害剤) の現在の治験進行状況、主要企業のプロファイルといった情報を盛り込んでお届けいたします。

第1章 イントロダクション:がん増殖阻害剤

第2章 がん増殖阻害剤の分類

第3章 がん増殖阻害剤の機序

第4章 世界のがん増殖阻害剤市場の概要

  • 現在の市場シナリオ
  • がん増殖阻害剤の臨床パイプラインの概要

第5章 世界のがん増殖阻害剤市場のダイナミクス

  • 有利な市場パラメーター
  • 事業化に当たっての課題

第6章 世界のがん増殖阻害剤市場の将来展望

第7章 がんチロシンキナーゼの臨床分析:企業別・適応症別・相別

  • 不明
  • 研究段階
  • 前臨床
  • 臨床
  • 第I相
  • 第I/II相
  • 第II相
  • 第II/III相
  • 第III相
  • 登録前
  • 登録済み

第8章 上市済みがんチロシンキナーゼの臨床分析

第9章 HDAC阻害剤の臨床分析:企業別・適応症別・相別

  • 研究段階
  • 前臨床
  • 第I相
  • 第I/II相
  • 第II相
  • 第III相
  • 登録後

第10章 上市済みHDAC阻害剤の臨床分析:企業別・適応症別

第11章 MTORタンパク質阻害剤の臨床分析:企業別・適応症別・相別

  • 研究段階
  • 前臨床
  • 臨床
  • 第I相
  • 第I/II相
  • 第II相
  • 第III相
  • 登録前
  • 登録後

第12章 上市済みMTORタンパク質阻害剤の臨床分析:企業別・適応症別

第13章 PI3K阻害剤の臨床分析:企業別・適応症別・相別

  • 研究段階
  • 前臨床
  • 第I相
  • 第I/II相
  • 第II相
  • 第II/III相
  • 第III相

第14章 上市済みPI3K阻害剤の臨床分析:企業別・適応症別

第15章 プロテアソーム阻害剤の臨床分析:企業別・適応症別・相別

  • 研究段階
  • 前臨床
  • 第I相
  • 第I/II相
  • 第II相
  • 第III相

第16章 上市済みプロテアソーム阻害剤の臨床分析:企業別・適応症別

第17章 競合情勢

  • Advaxis
  • Amgen
  • AstraZeneca
  • Bristol Mayer Squibb
  • Celldex Therapeutics
  • Eli Lily
  • GalaxoSmithKline
  • Genetech
  • ImmunoCellular Therapeutics
  • ImmunoGen
  • Merck
  • Novartis
  • Pfizer
  • Roche
  • Sanofi
  • Teva

図表一覧

目次

Pharmaceutical industry consists of various products for cancer treatment and several years of research along with significant investments have helped in developing many innovative products. Every year, new cancer therapeutic belonging to different drug category is introduced across the globe. Cancer growth inhibitors are recent additions as compared to conventional therapeutics which have modest pharmacological potential. Pharmaceutical companies have been able to introduce newer cancer growth inhibitors for different cancer categories to overcome therapeutic and commercialization barriers. Due to higher investments in research and development, their clinical pipeline is becoming stronger and novel cancer growth inhibitors for different cancers are entering in global market. Their rate of market introduction is expected to increase in coming years due to technological advancements and increased funding. Consequently, market introduction of these cancer growth inhibitors is expected to offer severe competition to existing cancer therapeutics in global market.

Cancer growth inhibitors market shows overlapping boundaries due to which it becomes difficult to demarcate different categories. For instance, a tyrosine kinase may be a small molecules or a large molecule because they have same inhibitory molecule. On the other hand, they may inhibit cellular processes and belong to different molecular classes. Despite these differences, cancer growth inhibitors occupy large market shares and targeted therapeutics seems to be the major contenders. They have high safety and efficacy profiles along with minimized side effects due to which large number of patients are including them as a part of their regular therapeutic regime. In coming years, they are expected to become main focus of pharmaceutical companies because conventional cancer therapies like chemotherapy have proved to have modest efficacy. In future, their therapeutic efficacy is expected to increase and many innovative products are at different phases of clinical development due to which their global market is expected to witness steady growth.

Clinical pipeline of cancer growth inhibitors is increasing due to innovations and potential competition from newly developed cancer drugs. Pharmaceutical companies are focusing on approaches like utilization of next generation sequencing and computerized simulation to prevent undue wastage of time and resources. Relapse is another biggest issues associated with conventional cancer therapeutics which could be prevented with the help of cancer growth inhibitors. Innovative cancer growth inhibitors are expected to increase average survival time and decrease mortality rates. These factors are expected to increase the demand for cancer growth inhibitors but still lots of modalities have to be streamlined in order to offer sustainable competition to newly coming cancer therapeutics belonging to other drug categories. One of the major steps in order to overcome these shortcomings could be the utilization of high end technology.

Cancer Growth Inhibitors Covered in Report:

  • Cancer Tyrosine Kinase
  • Proteasome Inhibitors
  • MTOR Protein Inhibitors
  • Histone Deacetylase Inhibitors (HDAC inhibitors)
  • PI3k

"Cancer Growth Inhibitors Market & Clinical Pipeline Analysis" Report Highlight:

  • Introduction & Classification of Cancer Growth Inhibitors
  • Cancer Growth Inhibitors Clinical Pipeline by Company, Indication & Phase
  • Cancer Growth Inhibitors Clinical Pipeline: 629 Drugs
  • Markets Cancer Growth Inhibitors: 48 Drugs
  • Tyrosine Kinase Dominates Cancer Growth Inhibitors Pipeline: 394 Drugs
  • HDAC Inhibitors Clinical Pipeline: 65 Drugs
  • MTOR Protein Inhibitors Clinical Pipeline: 62 Drugs
  • PI3k Clinical Pipeline: 89 Drugs
  • Proteasome Inhibitors Clinical Pipeline: 19 Drugs
  • Global Cancer Growth Inhibitors Market Future Prospects

Table of Contents

1. Introduction to Cancer Growth Inhibitors

2. Classification of Cancer Growth Inhibitors

3. Cancer Growth Inhibitors Mechanism

4. Global Cancer Growth Inhibitors Market Overview

  • 4.1 Current Market Scenario
  • 4.2 Cancer Growth Inhibitors Clinical Pipeline Overview

5. Global Cancer Growth Inhibitors Market Dynamics

  • 5.1 Favorable Market Parameters
  • 5.2 Commercialization Challenges

6. Global Cancer Growth Inhibitors Market Future Prospects

7. Cancer Tyrosine Kinase Clinical Insight by Company, Indication & Phase

  • 7.1 Unknown
  • 7.2 Research
  • 7.3 Preclinical
  • 7.4 Clinical
  • 7.5 Phase-I
  • 7.6 Phase-I/II
  • 7.7 Phase-II
  • 7.8 Phase-II/III
  • 7.9 Phase-III
  • 7.10 Preregistration
  • 7.11 Registered

8. Marketed Cancer Tyrosine Kinase Clinical Insight

9. HDAC Inhibitors Clinical Insight by Company, Indication & Phase

  • 9.1 Research
  • 9.2 Preclinical
  • 9.3 Phase-I
  • 9.4 Phase-I/II
  • 9.5 Phase-II
  • 9.6 Phase-III
  • 9.7 Registered

10. Marketed HDAC Inhibitors Clinical Insight by Company & Indication

11. MTOR Protein Inhibitors Clinical Insight by Company, Indication & Phase

  • 11.1 Research
  • 11.2 Preclinical
  • 11.3 Clinical
  • 11.4 Phase-I
  • 11.5 Phase-I/II
  • 11.6 Phase-II
  • 11.7 Phase-III
  • 11.8 Preregistration
  • 11.9 Registered

12. Marketed MTOR Protein Inhibitors Clinical Insight by Company & Indication

13. PI3K Inhibitors Clinical Insight by Company, Indication & Phase

  • 13.1 Research
  • 13.2 Preclinical
  • 13.3 Phase-I
  • 13.4 Phase-I/II
  • 13.5 Phase-II
  • 13.6 Phase-II/III
  • 13.7 Phase-III

14. Marketed PI3K Inhibitors Clinical Insight by Company & Indication

15. Proteasome Inhibitors Clinical Insight by Company, Indication & Phase

  • 15.1 Research
  • 15.2 Preclinical
  • 15.3 Phase-I
  • 15.4 Phase-I/II
  • 15.5 Phase-II
  • 15.6 Phase-III

16. Marketed Proteasome Inhibitors Clinical Insight by Company & Indication

17. Competitive Landscape

  • 17.1 Advaxis
  • 17.2 Amgen
  • 17.3 AstraZeneca
  • 17.4 Bristol Mayer Squibb
  • 17.5 Celldex Therapeutics
  • 17.6 Eli Lily
  • 17.7 GalaxoSmithKline
  • 17.8 Genetech
  • 17.9 ImmunoCellular Therapeutics
  • 17.10 ImmunoGen
  • 17.11 Merck
  • 17.12 Novartis
  • 17.13 Pfizer
  • 17.14 Roche
  • 17.15 Sanofi
  • 17.16 Teva

List of Figures

  • Figure 1-1: Benefits of Cancer Growth Inhibitors
  • Figure 1-2: Functions of Cancer Growth Inhibitors
  • Figure 1-3: Improvement Required for Cancer Growth Inhibitor
  • Figure 2-1: Cancer Growth Inhibitors Classification
  • Figure 2-2: Different Cancer Growth Inhibitors on the Basis of their Targets
  • Figure 3-1: Generalized Working of Cancer Growth Inhibitors
  • Figure 3-2: Mechanism of Bortezomib
  • Figure 3-3: Mechanism of Vismodegib
  • Figure 3-4: Mechanism of Everolimus
  • Figure 3-5: Mechanism of Bevacizumab
  • Figure 3-6: Mechanism of Imatinib
  • Figure 4-1: Cancer Growth Inhibitors Pipeline by Phase(%), 2015
  • Figure 4-2: Cancer Growth Inhibitors Pipeline by Phase (Number), 2015
  • Figure 4-3: Cancer Tyrosine Kinase Disease Pipeline by Phase (%), 2015
  • Figure 4-4: Cancer Tyrosine Kinase Disease Pipeline by Phase (Numbers), 2015
  • Figure 4-5: HDAC Pipeline by Phase (%), 2015
  • Figure 4-6: HDAC Pipeline by Phase (Number), 2015
  • Figure 4-7: Discontinued HDAC Pipeline by Phase (%), 2015
  • Figure 4-8: Discontinued HDAC Pipeline by Phase (Number), 2015
  • Figure 4-9: MTOR Protein Inhibitors Pipeline by Phase (%), 2015
  • Figure 4-10: MTOR Protein Inhibitors Pipeline by Phase (Number), 2015
  • Figure 4-11: Discontinued MTOR Protein Inhibitors Pipeline by Phase (%), 2015
  • Figure 4-12: Discontinued MTOR Protein Inhibitors Pipeline by Phase (Number), 2015
  • Figure 4-13: PI3K Pipeline by Phase (%), 2015
  • Figure 4-14: PI3K Pipeline by Phase (Number), 2015
  • Figure 4-15: Discontinued PI3K Pipeline by Phase (%), 2015
  • Figure 4-16: Discontinued PI3K Pipeline by Phase (Number), 2015
  • Figure 4-17: Proteasome Inhibitors Pipeline by Phase (%), 2015
  • Figure 4-18: Proteasome Inhibitors Pipeline by Phase (Number), 2015
  • Figure 4-19: No Development Reported Proteasome Inhibitors Pipeline by Phase (%), 2015
  • Figure 4-20: No Development Reported Proteasome Inhibitors Pipeline by Phase (Number), 2015
  • Figure 5-1: Global Cancer Growth Inhibitors Market Favorable Parameters
  • Figure 5-2: Cancer Growth Inhibitors Market Commercialization Challenges
  • Figure 17-1: Advaxis Clinical Pipeline
  • Figure 17-2: Celldex Therapeutics Clinical Pipeline
  • Figure 17-3: ImmunoCellular Therapeutics Clinical Pipeline
  • Figure 17-4: ImmunoGen Clinical Pipeline
Back to Top